Search results
Results from the WOW.Com Content Network
The Harvard School of Public Health and Dana-Farber/Harvard Cancer Center have created a Cancer FactFinder website, which is available in 9 languages.
Irene Ghobrial is an American-Egyptian physician who is a professor at the Dana–Farber Cancer Institute [2] and Harvard Medical School, [1] [3] where her research investigates early detection, mechanisms of disease progression and early interception of multiple myeloma.
In 2014, Freeman received the William B. Coley Award along with Tasuku Honjo, Lieping Chen and Arlene Sharpe. [3]In 2017, Freeman was one of the winners of the Warren Alpert Foundation Prize, and in 2022 he was elected to the American Academy of Arts and Sciences and the National Academy of Sciences.
Dana–Farber Cancer Institute (DFCI) is a comprehensive cancer treatment and research center in Boston, Massachusetts.Dana-Farber is the founding member of the Dana-Farber/Harvard Cancer Center, Harvard's Comprehensive Cancer Center designated by the National Cancer Institute, and one of the 15 clinical affiliates and research institutes of Harvard Medical School.
A machine-learning algorithm is then used to interpret the results, identifying similar features and helping to classify samples. A pilot study using samples from 12 breast cancer patients and 12 ...
The chaotic pattern of chromosomal abnormalities seen in most of the test results associated with cancer was “a very important” finding in the study, said Dr. Britta Weigelt, a molecular ...
In medicine, a clinical study report (CSR) on a clinical trial is a document, typically very long, providing much detail about the methods and results of a trial. A CSR is a scientific document addressing efficacy and safety, not a sales or marketing tool; its content is similar to that of a peer-reviewed academic paper. [ 1 ]
In 2008, the Dana-Farber Cancer Institute in Boston reported two-year overall survival of 53% and event-free survival of 70% (median age at diagnosis of 26 months). [7] In 2013, the Medical University of Vienna reported five-year overall survival of 100%, and event-free survival of 89% (median age at diagnosis of 24 months).